1. Home
  2. KALV vs CVLG Comparison

KALV vs CVLG Comparison

Compare KALV & CVLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • CVLG
  • Stock Information
  • Founded
  • KALV N/A
  • CVLG 1986
  • Country
  • KALV United States
  • CVLG United States
  • Employees
  • KALV N/A
  • CVLG N/A
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • CVLG Trucking Freight/Courier Services
  • Sector
  • KALV Health Care
  • CVLG Industrials
  • Exchange
  • KALV Nasdaq
  • CVLG Nasdaq
  • Market Cap
  • KALV 551.2M
  • CVLG 492.4M
  • IPO Year
  • KALV N/A
  • CVLG 1994
  • Fundamental
  • Price
  • KALV $13.62
  • CVLG $19.10
  • Analyst Decision
  • KALV Strong Buy
  • CVLG Buy
  • Analyst Count
  • KALV 8
  • CVLG 1
  • Target Price
  • KALV $26.43
  • CVLG $36.00
  • AVG Volume (30 Days)
  • KALV 1.2M
  • CVLG 121.4K
  • Earning Date
  • KALV 11-10-2025
  • CVLG 10-22-2025
  • Dividend Yield
  • KALV N/A
  • CVLG 1.48%
  • EPS Growth
  • KALV N/A
  • CVLG N/A
  • EPS
  • KALV N/A
  • CVLG 1.18
  • Revenue
  • KALV $1,426,000.00
  • CVLG $1,146,429,000.00
  • Revenue This Year
  • KALV N/A
  • CVLG $4.11
  • Revenue Next Year
  • KALV $234.65
  • CVLG $5.94
  • P/E Ratio
  • KALV N/A
  • CVLG $16.10
  • Revenue Growth
  • KALV N/A
  • CVLG 1.62
  • 52 Week Low
  • KALV $7.30
  • CVLG $17.46
  • 52 Week High
  • KALV $17.28
  • CVLG $30.19
  • Technical
  • Relative Strength Index (RSI)
  • KALV 70.91
  • CVLG 32.64
  • Support Level
  • KALV $10.55
  • CVLG $19.08
  • Resistance Level
  • KALV $13.44
  • CVLG $20.02
  • Average True Range (ATR)
  • KALV 0.65
  • CVLG 0.60
  • MACD
  • KALV 0.36
  • CVLG -0.03
  • Stochastic Oscillator
  • KALV 94.79
  • CVLG 9.42

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About CVLG Covenant Logistics Group Inc.

Covenant Logistics Group Inc together with its wholly-owned subsidiaries offers truckload transportation and freight brokerage services to customers throughout the continental United States. The company's reportable segments include Expedited, Dedicated Services, Managed Freight and Warehousing. Expedited segment provides truckload services to customers with high service freight and delivery standards. Dedicated segment provides customers with committed truckload capacity over contracted periods with the goal of three to five years in length. Managed Freight segment includes brokerage services and TMS. Warehousing segment provides day-to-day warehouse management services to customers who have chosen to outsource this function. Majority of revenue is generated from expedited segment.

Share on Social Networks: